Akari Therapeutics Dividend

Dividend criteria checks 0/6

Akari Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$1.26
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Akari Therapeutics GAAP EPS of $0.00

Sep 27

Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?

Sep 20

Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment

Jul 28

Akari Therapeutics GAAP EPS of $0.00

Jul 20

Patient completes course with Akari's stem cell transplant related complication treatment

Jul 07

We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate

Dec 31

Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan

Apr 28

Akari Therapeutics reports FY results

Apr 21

We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully

Mar 15

Akari Therapeutics' lead candidate shows encouraging preclinical action against inflammatory eye disease

Dec 03

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if AKTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AKTX's dividend payments have been increasing.

Dividend Yield vs Market

Akari Therapeutics Dividend Yield vs Market

How does AKTX dividend yield compare to the market?
Segment	Dividend Yield
Company (AKTX)	n/a
Market Bottom 25% (US)	1.6%
Market Top 25% (US)	4.8%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (AKTX)	n/a

Notable Dividend: Unable to evaluate AKTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AKTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate AKTX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AKTX has not reported any payouts.

Akari Therapeutics Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Akari Therapeutics Receives a Letter from the Listing Qualifications Staff of the Nasdaq Capital Market

New minor risk - Share price stability

New major risk - Shareholder dilution

New major risk - Market cap size

Akari Therapeutics, Plc (NasdaqCM:AKTX) entered into a definitive agreement to acquire Peak Bio, Inc. (OTCPK:PKBO).

Akari Therapeutics Appoints Samir R. Patel, M.D. to Board of Directors

Akari Therapeutics, Plc announced that it expects to receive $2 million in funding

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Akari Therapeutics, Plc Announces Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs, Effective September 1, 2023

Akari Therapeutics, plc Grants Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Akari Therapeutics, plc Announces Appointment of Wendy Dicicco as Interim Chief Financial Officer

Less than half of directors are independent

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Akari Therapeutics, plc Announces Updates on the Development of Long-Acting Pas-Nomacopan as A Potential Treatment for Geographic Atrophy

Akari Therapeutics, plc Announces Management Appointments

Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2023

Akari Therapeutics, Plc Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy

Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric Hsct-Tma into Pivotal Part B and Addition of A New Pipeline Program Developing Nomacopan for Hsct-Tma in Adults

Price target decreased to US$4.00

Insufficient new directors

Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of nomacopan for the Treatment of Pediatric HSCT-TMA

Akari Therapeutics Announces the Appointment of John F. Neylan, III as Executive Vice President, Chief Medical Officer

Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Akari Therapeutics GAAP EPS of $0.00

Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?

Akari Therapeutics, plc Announces That It Is Prioritizing Two Pipeline Programs

Insufficient new directors

Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy

Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment

Akari Therapeutics GAAP EPS of $0.00

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase Iii Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy

Patient completes course with Akari's stem cell transplant related complication treatment

Akari Therapeutics, Plc Appoints Melissa Bradford-Klug as Chief Operating Officer, Effective July 1, 2022

Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2022

Akari Therapeutics, Plc Presents Results from the CASCADE and CORONET Studies in COVID-19

Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology

Akari Therapeutics, Plc Presents Positive Results from Two Preclinical Studies of Its Lead Asset, Investigational Nomacopan

Insufficient new directors

Akari Therapeutics, Plc Appoints Rachelle Jacques as President and Join its Board of Directors

Akari Therapeutics, Plc Appoints Rachelle Jacques as President and Join its Board of Directors

Akari Therapeutics, plc Announces New Data Showing That Clinical Outcomes in U.S. Army Trauma Patients Correlate with Complement Activation

Akari Therapeutics, plc Announces Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases

Akari Therapeutics, Plc announces FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies

We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate

Akari Therapeutics, Plc Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders

Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid

Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan

Akari Therapeutics reports FY results

We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully

Akari Therapeutics, Plc Announces a Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research for Nomacopan in Trauma

Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis

New 90-day high: US$3.88

Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to Treat Neuropathic Pain and Dermatological Disease

Do Institutions Own Akari Therapeutics, Plc (NASDAQ:AKTX) Shares?

New 90-day high: US$2.05

Read This Before Selling Akari Therapeutics, Plc (NASDAQ:AKTX) Shares

New 90-day high: US$2.00

Akari Therapeutics, Plc Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Akari Therapeutics updates trial progress; returns to profitability

Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease

Akari Therapeutics' lead candidate shows encouraging preclinical action against inflammatory eye disease

New 90-day low: US$1.50

Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia

Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid

New 90-day low - US$1.64

New 90-day low - US$1.84

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies